X
(All Fields are required)
Issue Brief

MRSA: A Deadly Pathogen with Fewer and Fewer Treatment Options


MRSA: A Deadly Pathogen with Fewer and Fewer Treatment Options

Staphylococcus aureus, or staph, is a common bacterium that exists in our environment and our bodies. Most of the time it does no harm. Sometimes, however, it can cause infection and require treatment. MRSA refers to strains of S. aureus that are resistant to the antibiotic methicillin and a host of other drugs used to treat infection.

Vital Statistics
• MRSA is responsible for an estimated 19,000 U.S. deaths1 and 368,000 hospitalizations per year.2
• Patients with MRSA can be twice as likely to die as patients with staph infections that can be treated with methicillin.3
• Annual costs of treating hospitalized MRSA patients are between $3.2 billion and $4.2 billion in the United States.4

MRSA Is Becoming Resistant to a Growing Number of Antibiotics
MRSA is most commonly resistant to antibiotics used to treat conventional staph infections.7

• Beta-lactams (penicillins and cephalosporins)
• Fluoroquinolones (e.g., levofloxacin)
• Macrolides (e.g., erythromycin, azithromycin)

MRSA can usually be treated with “last-resort” antibiotics, but some resistance has been reported to:8
• Clindamycin9,10
• Vancomycin11
• Linezolid and daptomycin11,12 (the last two novel drugs approved to treat drug-resistant S. aureus infections).

Related Items

• MRSA on the Appalachian Trail: The Story of Steve Weisel
• Jamel Sawyer: A Young Man Fights MRSA
• Antibiotics and Innovation Project

Date added:
Apr 3, 2012
Project:
Antibiotics and Innovation Project
Topics:
Food Safety, Antibiotic Innovation
References:
Collapse All
close

References:

1 R. M. Klevens et al., “Invasive Methicillin-Resistant Staphylococcus Aureus Infections in the United States,” JAMA 298, no. 15 (2007): 1763-71.
2 Agency for Healthcare Research and Quality (AHRQ), Center for Delivery Organization, and Markets, Healthcare Costs and Utilization Project, Nationwide Inpatient Sample, 1993-2005.
3 M. Whitby, M.L. McLaws, and G. Berry. “Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: a meta-analysis,” Med J Aust 175, no. 5 (2001):264-7.
4 E. Rojas and L. Liu, “Estimating the annual hospital excess cost of methicillin-resistant Staphylococcus aureus infections in the United States,” presented at International Society for Pharmacoeconomics and Outcomes Research (IPSOR) Tenth Annual International Meeting, Washington, DC, May 2005.
5 H. Boucher, L. G. Miller, and R. R. Razonable, “Serious Infections Caused by Methicillin-Resistant Staphylococcus Aureus,” Clin Infect Dis 51 Suppl 2(2010): S183-97.
6 A. Elixhauser and C. Steiner, “Infections with Methicillin-Resistant Staphylococcus Aureus (MRSA) in U.S. Hospitals, 1993–2005,” HCUP Statistical Brief #35. July 2007. Agency for Healthcare Research and Quality, Rockville, MD. www.hcup-us.ahrq.gov/reports/statbriefs/sb35.pdf.
7 K. Chua et al., “Antimicrobial Resistance: Not Community-Associated Methicillin-Resistant Staphylococcus Aureus (CA-MRSA)! A Clinician’s Guide to Community MRSA — Its Evolving Antimicrobial Resistance and Implications for Therapy,” Clin Infect Dis 52, no. 1 (2011): 99-114.
8 C. Liu et al., “Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in Adults and Children,“ Clin Infect Dis 52, no. 3 (2011): e18-55.
9 L. L. Han et al., “High Frequencies of Clindamycin and Tetracycline Resistance in Methicillin-Resistant Staphylococcus Aureus Pulsed-Field Type Usa300 Isolates Collected at a Boston Ambulatory Health Center,” J Clin Microbiol 45, no. 4 (2007): 1350-2.
10 R. E. Mendes et al., “Characterization of Baseline Methicillin-Resistant Staphylococcus Aureus Isolates Recovered from Phase Iv Clinical Trial for Linezolid,” J Clin Microbiol 48, no. 2 (2010): 568-74.
11 A. Mangili et al., “Daptomycin-Resistant, Methicillin-Resistant Staphylococcus Aureus Bacteremia,” Clin Infect Dis 40, no. 7 (2005): 1058-60.
12 P. Wilson et al., “Linezolid Resistance in Clinical Isolates of Staphylococcus Aureus,” J Antimicrob Chemother 51, no. 1 (2003): 186-8.

Related Resources

FDA Releases Draft Guidance on Antibacterial Drug Development

Other Resource

Nearly a year after the enactment of the Generating Antibiotic Incentives Now Act, the U.S. Food and Drug Administration has released draft guidance for industry on developing antibacterial therapies for patients with unmet medical needs.

More

Multistate Foodborne Illness Outbreaks

Data Visualization

In January 2011, President Barack Obama signed the FDA Food Safety Modernization Act (FSMA) into law, signaling the first major update to our nation’s food safety oversight framework since the Great Depression. Despite widespread support for the legislation and its implementation, the Obama administration still has not issued all of the proposed rules under FSMA.

More

''Congress Shouldn't Weaken Food Safety Laws''

Opinion

"Being a Minnesotan, Jeff Almer searched for a polite term to describe how he feels about a congressional push to roll back the new food safety laws his family fought for when his elderly mother died after eating ­salmonella-laced peanut butter in late 2008."

More

Drug Development for Limited Populations: A New Proposed Pathway

Issue Brief
The lack of new antibiotics and the rise in drug resistance have rendered some serious and life-threatening infections untreatable, and the health care community is searching for ways to bring innovative new drugs to patients whose treatment options are limited or nonexistent. More

''For Our Kids' Sake, Food Safety Must Be a Priority''

Opinion

As a pediatrician, my No. 1 concern is to keep children safe and healthy. Inside the walls of my office, I can provide services and counseling to help do just that, whether by giving an infant her first childhood vaccine, providing a mental health screening to an adolescent patient or counseling parents about how to keep their homes as safe as possible. Unfortunately, there are some threats to children's health that are beyond my control, including the food they consume.

More